αααααβααΎαSBMFF β’ OTCMKTS
add
Sino Biopharmaceutical Ltd
0.41$
14 ααααΆ, 12:20:21 AM ααααβααα -5 · USD · OTCMKTS · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
ααΆαβα αα»αααΌααααααααααΆαα
α»ααααααΈαα
α’αΆαααα·α
αα·αααΈαα»α
0.41$
α
ααααααα½αααααΆαα
α»αααααα
0.31$ - 0.47$
ααΎαβαα»αβααΈααααΆα
54.15Β αααΈααΆα HKD
ααα ααα½αααΌαααααα
364.00
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
-
ααΆααααααΌαα
αααα
HKG
ααααααΆαααΈααααΆα
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
| (CNY) | αα·αα»ααΆ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌα | 7.94Β αααΈααΆα | 11.14% |
α
αααΆαααααα·ααααα·ααΆα | 4.78Β αααΈααΆα | 10.58% |
α
αααΌααα»ααα | 1.51Β αααΈααΆα | 139.69% |
ααααΆααα
αααααα»ααα | 19.01 | 115.78% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | β | β |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | 1.98Β αααΈααΆα | 8.88% |
α’ααααΆαααααααααΆαααααα·αααααΆα | 16.99% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
| (CNY) | αα·αα»ααΆ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 13.18Β αααΈααΆα | -15.93% |
ααααααααα»α | 66.70Β αααΈααΆα | 1.62% |
ααΆαααα½ααα»αααααΌαααα»α | 24.58Β αααΈααΆα | -15.76% |
ααΌαβααααα»α | 42.12Β αααΈααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 18.21Β αααΈααΆα | β |
ααααααααααΉαααααα
| 0.23 | β |
ααα
ααααααΎαααααα | 6.50% | β |
ααα
ααααααΎααΎααα»α | 8.37% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
| (CNY) | αα·αα»ααΆ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌααα»ααα | 1.51Β αααΈααΆα | 139.69% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | 1.54Β αααΈααΆα | 15.25% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | -1.02Β αααΈααΆα | 49.91% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | -2.05Β αααΈααΆα | -1.42% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | -1.52Β αααΈααΆα | 43.37% |
ααα αΌαααΆα
αααααΆααααααα | 1.09Β αααΈααΆα | 36.59% |
α’αααΈ
Sino Biopharmaceutical Limited, shortly Sino Biopharm, is a pharmaceutical conglomerate in China. The Company was listed on the Hong Kong Stock Exchange in 2000 and included in 2013 as a constituent stock of MSCI Global Standard Indices β MSCI China Index, Hang Seng Index in 2018, Hang Seng China Enterprises Index in 2019, and Hang Seng Connect Biotech 50 Index and Hang Seng China 25 Index in 2020.
The Groupβs principal subsidiaries include: Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Beijing Tide Pharmaceutical Co. Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd. and invoX Pharma Limited. Its products including biopharmaceutical and chemical medicines are used in a host of therapeutic areas, such as tumors, liver diseases, respiratory system diseases and surgery/analgesia. Wikipedia
CEO
ααΆααααααΎαα‘αΎα
2000
αααααβαααααΆα
αα»ααααα·α
24,437
